A review of dopamine agonist therapy in type 2 diabetes and effects on cardio-metabolic parameters

Dopamine action appears to play a role in changes that are seen in obesity, metabolic syndrome and type 2 diabetes mellitus. Bromocriptine-QR (Quick Release), a dopamine agonist, is approved for use in treatment of type 2 diabetes. It has demonstrated modest improvement in glycemic parameters, cholesterol and weight in certain cohorts. Limited data using cabergoline, a long-acting dopamine agonist, also demonstrate glycemic efficacy. Additionally, bromocriptine-QR appears to have a favorable cardiovascular risk reduction. The direct mechanism by which bromocriptine-QR, or central dopamine agonism, achieves modest glycemic control and favorable cardio-metabolic profile is unclear. This relationship appears to be more complex than the historical explanation of resetting the circadian clock and may further be elucidated using data in individuals with hyperprolactinemia and prolactinoma. (C) 2015 Primary Care Diabetes Europe. Published by Elsevier Ltd. All rights reserved.